Utility of fDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up

Annals of Surgical Oncology

Volumn 17, Issue 6, 2010, Pages 1657-1661

  Aukema, Tjeerd S ^a   Valdés Olmos, Renato A ^a   Korse, Catharina M ^a   Kroon, Bin B R ^a   Wouters, Michel W J M ^a   Vogel, Wouter V ^a   Bonfrer, Johannes M G ^a   Nieweg, Omgo E ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN S100B;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATIENT CARE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; SKIN BIOPSY; SKIN SURGERY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MELANOMA; MIDDLE AGED; NERVE GROWTH FACTORS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

EID: 77954814945     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0963-x     Document Type: Article

References (24)

1. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898-1902
2. Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer. 2003;39: 164-169 (Pubitemid 36057065)
3. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386-392
4. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38-44.
5. Smit LH, Nieweg OE, Mooi WJ, Bonfrer JM, Haanen JB, Kroon BB, et al. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res. 2008; 28:2297-2302
6. Holder WD, Jr, White RL, Jr, Zuger JH, Easton EJ, Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764-769
7. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178-1187
8. Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med. 2004;45:1323-1327
9. Akcali C, Zincirkeser S, Erbagcy Z, Akcali A, Halac M, Durak G, et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res. 2007;35:547-553
10. Kitajima K, Nakamoto Y, Okizuka H, Onishi Y, Senda M, Suganuma N, et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med. 2008;22:595-602.
11. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181-187
12. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers. 2005;20:34-42.
13. Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol. 2000;143:256-268
14. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999; 56:338-344
15. Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21:1311-1316
16. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009; 16:3455-3462
17. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824-831
18. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140:1065-1071
19. Hamberg AP, Korse CM, Bonfrer JM, De Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45-49
20. Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwarz M, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res. 2000; 10:451-459
21. Strobel K, Skalsky J, Kalff V, Baumann K, Seifert B, Joller- Jemelka H, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging. 2007;34:1366-1375
22. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210:39-44.
23. Ho Shon IA, Chung DK, Saw RP, Thompson JF. Guidelines for imaging in cutaneous melanoma. Nucl Med Commun. 2008;29: 877-879
24. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45 Suppl 1:72S- 81S.